Tefferi A, Pardanani A. Essential Thrombocythemia. N Engl J Med. 2019 Nov 28. 381 (22):2135-2144. [QxMD MEDLINE Link].
Epstein E, Goedel A. Hammorhagische thrombocythamie bei vascularer schrumpfmilz. Virch Arch (Pathol Anat). 1934. 292:233.
Ashorobi D, Gohari P. Essential Thrombocytosis. 2021 Jan. [QxMD MEDLINE Link]. [Full Text].
Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 1999 Jan 15. 93(2):417-24. [QxMD MEDLINE Link]. [Full Text].
Rumi E, Cazzola M. How we treat essential thrombocythemia. Blood. 2016 Aug 25. [QxMD MEDLINE Link].
Ruggeri M, Gisslinger H, Tosetto A, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol. 2002 Sep. 71(1):1-6. [QxMD MEDLINE Link]. [Full Text].
Harrison CN, Donohoe S, Carr P, et al. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost. 2002 May. 87(5):802-7. [QxMD MEDLINE Link].
Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol. 1996 May. 52(1):14-20. [QxMD MEDLINE Link].
Kwon M, Osorio S, Muñoz C, Sánchez JM, Buno I, Díez-Martín JL. Essential thrombocythemia in patients with platelet counts below 600x10(9)/L: applicability of the 2008 World Health Organization diagnostic criteria revision proposal. Am J Hematol. 2009 Jul. 84(7):452-4. [QxMD MEDLINE Link].
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017 Jan. 92 (1):94-108. [QxMD MEDLINE Link].
Lee HS, Park LC, Lee EM, Lee SJ, Shin SH, Im H, et al. Incidence Rates and Risk Factors for Vascular Events in Patients With Essential Thrombocythemia: A Multicenter Study From Korea. Clin Lymphoma Myeloma Leuk. 2011 Nov 14. [QxMD MEDLINE Link].
Genetics Home Reference. Essential Thrombocythemia. U.S. National Library of Medicine. Available at http://ghr.nlm.nih.gov/condition/essential-thrombocythemia. 18 August 2020; Accessed: August 10, 2021.
Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014 Mar 6. 123 (10):1544-51. [QxMD MEDLINE Link].
Fabris F, Casonato A, Grazia del Ben M, De Marco L, Girolami A. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol. 1986 May. 63(1):75-83. [QxMD MEDLINE Link].
van Genderen PJ, Michiels JJ, van der Poel-van de Luytgaarde SC, van Vliet HH. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann Hematol. 1994 Aug. 69(2):81-4. [QxMD MEDLINE Link].
Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999 May. 61(1):10-5. [QxMD MEDLINE Link]. [Full Text].
Shrestha R, Giri S, Pathak R, Bhatt VR. Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia. World J Clin Oncol. 2016 Aug 10. 7 (4):324-30. [QxMD MEDLINE Link].
Yogarajah M, Tefferi A. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome. Mayo Clin Proc. 2017 Jul. 92 (7):1118-1128. [QxMD MEDLINE Link].
Rospond-Kubiak I, Oszkinis G, Kociecki J. Retinal Intra-arterial Thrombocytic Material Revealing Essential Thrombocythemia. JAMA Ophthalmol. 2016 Aug 11. 134 (8):e161111. [QxMD MEDLINE Link].
Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001 Jan. 76(1):22-8. [QxMD MEDLINE Link].
Girodon F, Bonicelli G, Schaeffer C, Mounier M, Carillo S, Lafon I, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Haematologica. 2009 Jun. 94(6):865-9. [QxMD MEDLINE Link]. [Full Text].
Appleby N, Angelov D. Clinical and laboratory assessment of a patient with thrombocytosis. Br J Hosp Med (Lond). 2017 Oct 2. 78 (10):558-564. [QxMD MEDLINE Link].
[Guideline] Harrison CN, Butt N, Campbell P, Conneally E, Drummond M, Green AR, et al. Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. Br J Haematol. 2014 Nov. 167 (3):421-3. [QxMD MEDLINE Link]. [Full Text].
Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017 Feb 9. 129 (6):680-692. [QxMD MEDLINE Link]. [Full Text].
Spanoudakis E, Margaritis D, Kotsianidis I, et al. Long-term bone marrow cultures (LTBMC) from essential thrombocythemia (ET) patients with or without JAK2617V>F mutation. Leuk Res. 2008 Oct. 32(10):1593-6. [QxMD MEDLINE Link].
Teofili L, Martini M, Cenci T, et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer. 2008 Oct 1. 123(7):1586-92. [QxMD MEDLINE Link].
Ohyashiki K, Kodama A, Ohyashiki JH. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development. Cancer Genet Cytogenet. 2008 Oct. 186(1):6-11. [QxMD MEDLINE Link].
Zhan H, Spivak JL. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Clin Adv Hematol Oncol. 2009 May. 7(5):334-42. [QxMD MEDLINE Link].
Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009 Jun 20. 27(18):2991-9. [QxMD MEDLINE Link].
Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018 Jan 10. 8 (1):2. [QxMD MEDLINE Link]. [Full Text].
Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27. 332(17):1132-6. [QxMD MEDLINE Link]. [Full Text].
Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7. 353(1):33-45. [QxMD MEDLINE Link]. [Full Text].
Aruch D, Mascarenhas J. Contemporary approach to essential thrombocythemia and polycythemia vera. Curr Opin Hematol. 2016 Mar. 23 (2):150-60. [QxMD MEDLINE Link].
Kanakura Y, Shirasugi Y, Yamaguchi H, Koike M, Chou T, Okamoto S, et al. A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia. Int J Hematol. 2018 Nov. 108 (5):491-498. [QxMD MEDLINE Link].
Godfrey AL, Campbell PJ, MacLean C, et al. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. J Clin Oncol. 2018 Aug 28. JCO2018788414. [QxMD MEDLINE Link]. [Full Text].
Tefferi A, Szuber N, Pardanani A, Hanson CA, Vannucchi AM, Barbui T, et al. Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. Am J Hematol. 2021 Jun 1. 96 (6):E182-E184. [QxMD MEDLINE Link]. [Full Text].
Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L, et al. Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets and dendritic cells in patients with JAK2V617F -positive essential thrombocythemia and polycythemia vera. Eur J Haematol. 2015 Sep 19. [QxMD MEDLINE Link].
Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, et al. Clinical and molecular response to interferon alpha therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015 Oct 20. [QxMD MEDLINE Link].
[Guideline] Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004 Feb. 89 (2):215-32. [QxMD MEDLINE Link]. [Full Text].
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015 Feb. 90 (2):162-73. [QxMD MEDLINE Link].
Schrickel L, Heidel FH, Sadjadian P, Becker T, Kolatzki V, Hochhaus A, et al. Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. J Cancer Res Clin Oncol. 2021 May. 147 (5):1481-1491. [QxMD MEDLINE Link].
Edahiro Y, Yasuda H, Gotoh A, Morishita S, Suzuki T, Takeda J, et al. Interferon therapy for pregnant patients with essential thrombocythemia in Japan. Int J Hematol. 2021 Jan. 113 (1):106-111. [QxMD MEDLINE Link].
Gangat N, Tefferi A. Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. Am J Hematol. 2021 Mar 1. 96 (3):354-366. [QxMD MEDLINE Link].
Pieri L, Pancrazzi A, Pacilli A, Rabuzzi C, Rotunno G, Fanelli T, et al. JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood. 2015 May 21. 125 (21):3352-3. [QxMD MEDLINE Link]. [Full Text].
Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017 Oct 26. 130 (17):1889-1897. [QxMD MEDLINE Link].
Nelson R. FDA Approves Fedratinib for the Treatment of Myelofibrosis. Medscape Medical News. Available at https://www.medscape.com/viewarticle/916928. August 16, 2019; Accessed: August 16, 2019.
Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, et al. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med. 2015 Sep 3. 373 (10):908-19. [QxMD MEDLINE Link].
Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009 May 14. 113(20):4829-33. [QxMD MEDLINE Link].
Gugliotta L, Marchioli R, Fiacchini M, et al. Epidemiological, diagnostic, therapeutic and prognostic aspects of essential thrombocythemia in a retrospective study of the GIMMC group in two thousand patients [abstract]. Blood. 1997. 90(suppl 1):348a.